These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
66. The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy. Mok TSK; Crino L; Felip E; Salgia R; De Pas T; Tan DSW; Chow LQM Cancer Treat Rev; 2017 Apr; 55():181-189. PubMed ID: 28427013 [TBL] [Abstract][Full Text] [Related]
67. Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations. Bearz A; Martini JF; Jassem J; Kim SW; Chang GC; Shaw AT; Shepard DA; Dall'O' E; Polli A; Thurm H; Zalcman G; Garcia Campelo MR; Penkov K; Hayashi H; Solomon BJ J Thorac Oncol; 2023 Nov; 18(11):1581-1593. PubMed ID: 37541389 [TBL] [Abstract][Full Text] [Related]
68. Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase-Positive Lung Cancer and CNS-Specific Relapse. Dagogo-Jack I; Oxnard GR; Evangelist M; Digumarthy SR; Lin JJ; Gainor JF; Murphy JF; Rabin MS; Heist RS; Muzikansky A; Shaw AT JCO Precis Oncol; 2022 May; 6():e2100522. PubMed ID: 35584349 [TBL] [Abstract][Full Text] [Related]
69. Dissecting the role of ALK double mutations in drug resistance to lorlatinib with in-depth theoretical modeling and analysis. Zhang X; Tong J; Wang T; Wang T; Xu L; Wang Z; Hou T; Pan P Comput Biol Med; 2024 Feb; 169():107815. PubMed ID: 38128254 [TBL] [Abstract][Full Text] [Related]
70. TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors. Amin AD; Li L; Rajan SS; Gokhale V; Groysman MJ; Pongtornpipat P; Tapia EO; Wang M; Schatz JH Oncotarget; 2016 Apr; 7(17):23715-29. PubMed ID: 27009859 [TBL] [Abstract][Full Text] [Related]
71. Rapid and durable response to fifth-line lorlatinib plus olaparib in an ALK -rearranged, BRCA2-mutated metastatic lung adenocarcinoma patient with critical tracheal stenosis: a case report. Jin C; He Z; Guo M; Liu S; Wang Y; Qiu J; Li C; Wu D Anticancer Drugs; 2022 Aug; 33(7):696-700. PubMed ID: 35324529 [TBL] [Abstract][Full Text] [Related]
72. Activation of IGF-1R pathway and NPM-ALK G1269A mutation confer resistance to crizotinib treatment in NPM-ALK positive lymphoma. Li Y; Wang K; Song N; Hou K; Che X; Zhou Y; Liu Y; Zhang J Invest New Drugs; 2020 Jun; 38(3):599-609. PubMed ID: 31177400 [TBL] [Abstract][Full Text] [Related]
73. Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer. Yu Y; Ou Q; Wu X; Bao H; Ding Y; Shao YW; Lu S Lung Cancer; 2019 Jan; 127():19-24. PubMed ID: 30642546 [TBL] [Abstract][Full Text] [Related]
74. From preclinical efficacy to 2022 (36.7 months median follow -up) updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK+ NSCLC. Ou SI; Lee ATM; Nagasaka M Crit Rev Oncol Hematol; 2023 Jul; 187():104019. PubMed ID: 37187318 [TBL] [Abstract][Full Text] [Related]
75. Comparative safety of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced anaplastic lymphoma kinase-mutated non-small cell lung cancer: Systematic review and network meta-analysis. Luo Y; Zhang Z; Guo X; Tang X; Li S; Gong G; Gao S; Zhang Y; Lin S Lung Cancer; 2023 Oct; 184():107319. PubMed ID: 37597303 [TBL] [Abstract][Full Text] [Related]